$655.76
▲ +0.7% Today
as of Jul 22, 16:53 ET
Last 30 days
Recent Press Releases & News
mixed
▲ 1
● 24
▼ 0
Cantor Fitzgerald Adjusts Price Target on Regeneron Pharmaceuticals to $750 From $785
Guggenheim Adjusts PT on Regeneron Pharmaceuticals to $1,000 From $995, Maintains Buy Rating
Goldman Sachs Adjusts Price Target on Regeneron Pharmaceuticals to $965 From $968, Maintains Buy Rating
Overview
52-week range
$476
$821
52% of range
Avg surprise (last 2)
+36.7%
Avg reaction (last 1)
-6.9%
0% positive
Latest IV / EM
52%
EM ±6.5% · $655 · Jul 31
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Mar 31, 2026 | Mar 2026 | $6.75 | — | — | — | — | financials |
| Tue Sep 30, 2025 | Sep 2025 | $13.62 | — | — | — | — | financials |
| Fri Aug 1, 2025 | Jun/2025 | $10.72 | $6.09 | +76.0% | — | — | earnings |
| Tue Apr 29, 2025 | Mar/2025 | $6.43 | $6.61 | -2.7% | — | -6.9% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $11.54 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $12.41 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $6.27 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $8.89 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $8.50 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Thu Jul 30, 2026 | Jun/2026 | BMO | $8.00 | $10.72 | -25.4% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $643M | — | $1.03B | $1.08B | $592M | — | $1.18B | $1.07B |
| Net income | $727M | — | $1.46B | $1.39B | $809M | — | $1.34B | $1.43B |
| EPS (diluted) | $6.75 | — | $13.62 | $12.81 | $7.27 | — | $11.54 | $12.41 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $2.96B | $3.12B | $2.51B | $2.00B | $3.09B | $2.49B | $2.01B | $1.92B |
| Inventory | $3.10B | $3.20B | $3.25B | $3.21B | $3.19B | $3.09B | $3.02B | $2.87B |
| Total current assets | $18.21B | $18.02B | $17.98B | $16.86B | $17.57B | $18.66B | $19.33B | $19.08B |
| Total assets | $40.87B | $40.56B | $40.17B | $38.22B | $37.55B | $37.76B | $37.44B | $36.09B |
| Long-term debt | $1.99B | $1.99B | $1.99B | $1.99B | $1.98B | $1.98B | $1.98B | $1.98B |
| Total liabilities | $9.45B | $9.30B | $9.21B | $8.28B | $8.16B | $8.41B | $8.12B | $7.88B |
| Total equity | $31.42B | $31.26B | $30.96B | $29.94B | $29.39B | $29.35B | $29.33B | $28.21B |